

It is indeed a delight to see the Second Edition of this blockbuster book, *Lung Cancer*, come to fruition. The success is a testament to the dedication and scientific vigour from the Editors-in-Chief, Jianxing He, Thomas D'Amico, Xiuyi Zhi; the Honorary Editors-in-Chief, Nanshan Zhong, Rafael Rosell, Heather Wakelee; as well as the Associate Editors, authors and supporting staff.

The landscape and management of lung cancer has changed dramatically in the last decade, perhaps more than any other thoracic disease. Advances in surgery and better understanding of cancer genetics to allow personalized drug therapies have provided ever more complex game changing treatment algorithms to fight this terrible disease. With increasing global adoption of lung cancer screening, the likely seismic shift in patient demographics and tumour characteristics could pose a challenge in diagnosis and treatment. The role of liquid biopsies, more targeted bespoke drug therapies, non-invasive endoscopic treatments and high precision surgery may gain even more importance.

In this book, *Lung Cancer*, the chapters from some of the most recognized and authoritative figures in their topic share updates, future developments and personal perspectives on these most researched and sometimes controversial areas in lung cancer management. Health professionals and researchers will find the information and scientific analyses highly useful for managing lung cancer and for developing their areas of interest.

**Calvin S. H. Ng, BSc, MBBS, MD, FRCSEd, FCCP, FAPSR**

*Department of Surgery, The Chinese University of Hong Kong,  
Prince of Wales Hospital, Shatin, N.T., Hong Kong, China*